Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 15/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591408 | 1.00 | CALCA (0.39) | CALCAALDH1A1CALCRL | |
| SCHEMBL29549518 | 1.00 | CALCA (0.39) | CALCAALDH1A1CALCRL | |
| SCHEMBL22796447 | 1.00 | CALCA (0.39) | CALCAALDH1A1CALCRL | |
| Hydrochloric Acid SCHEMBL29549660 | 0.99 | ALDH1A1 (0.40) | CALCAALDH1A1CALCRL | |
| Hydrochloric Acid SCHEMBL136451 | 0.99 | ALDH1A1 (0.40) | CALCAALDH1A1CALCRL | |
| Hydrochloric Acid SCHEMBL136450 | 0.99 | ALDH1A1 (0.40) | CALCAALDH1A1CALCRL | |
| Hydrochloric Acid SCHEMBL18788018 | 0.99 | ALDH1A1 (0.40) | CALCAALDH1A1CALCRL | |
| Hydrochloric Acid SCHEMBL18788017 | 0.99 | ALDH1A1 (0.40) | CALCAALDH1A1CALCRL | |
| Bromide SCHEMBL31628271 | 0.99 | CALCA (0.39) | CALCAALDH1A1CALCRL | |
| Trifluoroacetic Acid SCHEMBL31180101 | 0.92 | CALCA (0.38) | CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12178813-B2 | CGRP receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2024-12-31 | — | — | US | disclosed |
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-12-22 | — | — | US | disclosed |
| US-20210213011-A1 | CGRP RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-07-15 | — | — | US | disclosed |
| US-20210213011-A1 | CGRP RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-07-15 | — | — | US | disclosed |
| WO-2021127070-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-10888561-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-01-12 | — | — | US | disclosed |
| US-10888561-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-01-12 | — | — | US | disclosed |
| WO-2020249969-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-12-17 | — | — | WO | disclosed |
| US-20190231773-A1 | CGRP RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-08-01 | — | — | US | disclosed |
| US-20190231773-A1 | CGRP RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-08-01 | — | — | US | disclosed |
| WO-2011123232-A1 | CGRP RECEPTOR ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| US-7834007-B2 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834007-B2 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-7449586-B2 | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449586-B2 | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449586-B2 | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070049577-A1 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049577-A1 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| WO-2006060678-A2 | NOVEL PROCESSES FOR THE PREPARATION OF CGRP-RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060122250-A1 | Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | CALCA, CALCB, CALCRL | CALCA 1/4885ALDH1A1 2986/4885CALCRL 3/4885 |
| US-20070049577-A1 | CGRP antagonists | CALCRL, CALCR, CALCA | CALCA 3/4885ALDH1A1 2552/4885CALCRL 1/4885 |
| US-10888561-B2 | CGRP receptor antagonists | CALCRL, CALCR, VIPR1 | CALCA 18/4885ALDH1A1 1249/4885CALCRL 1/4885 |
| US-12178813-B2 | CGRP receptor antagonists | CALCRL, CALCR, VIPR1 | CALCA 18/4885ALDH1A1 1249/4885CALCRL 1/4885 |
| US-20060122250-A1 | Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof | CALCR, CALCRL, CALCB | CALCA 4/4885ALDH1A1 2702/4885CALCRL 2/4885 |
| US-20210213011-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, VIPR1 | CALCA 18/4885ALDH1A1 1249/4885CALCRL 1/4885 |
| US-20190231773-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, VIPR1 | CALCA 18/4885ALDH1A1 1249/4885CALCRL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.